Physician profile
Amitabh Kumar
NPI 1346215712
$1,794.45
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $34.47 · 2021: $47.85 · 2022: $705 · 2023: $427 · 2024: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.73 | 2019-2024 | |
| Olympus America INC. | $413.71 | 2019-2024 | Endoclot Phs, Hanarostent Lowaxtm Duodenum/Pylorus(Nnn), Visiglide |
| Boston Scientific Corporation | $150.89 | 2019-2022 | |
| Redhill Biopharma INC. | $131.02 | 2021-2022 | |
| Medtronic, INC. | $125.27 | 2022-2024 | Gi Genius |
| Takeda Pharmaceuticals U.S.A., INC. | $109.16 | 2022 | |
| Gilead Sciences, INC. | $68.20 | 2019 | |
| Janssen Biotech, INC. | $66.11 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.63 | 2019-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $42.28 | 2024 | Voquezna |
| Endogastric Solutions, INC | $40.50 | 2024 | Esophyx |
| Merck Sharp & Dohme LLC | $24.80 | 2024 | Dificid |
| Alexion Pharmaceuticals, INC. | $23.04 | 2022 | |
| Covidien LP | $20.49 | 2019 | |
| Ardelyx, INC. | $18.00 | 2023 | Ibsrela |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $17.02 | 2023 | Gimoti |
| Ironwood Pharmaceuticals, INC | $15.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitabh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.